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Background: In this study, we analyzed the characteristics of oseltamivir-resistant influenza A (H1N1) pdm09 virus
isolated from patients in mainland China during the influenza season from September 2013 through March 2014,
and provide guidance on which antiviral to be used for clinical treatment.
Methods: The all viruses collected from September 1, 2013 through March 31, 2014 were obtained from the
Chinese National Influenza Surveillance Network. A fluorescence-based assay was used to detect virus sensitivity to
neuraminidase inhibitors (NAIs). The hemagglutinin (HA) and neuraminidase (NA) gene of the oseltamivir-resistant
viruses were sequenced.
Results: A total of 24 (2.14 %) influenza A (H1N1) pdm09 viruses that were resistant to oseltamivir were identified.
These 24 viruses were isolated from 23 patients and no epidemiological link among them could be identified.
Except for one virus with the H275H/Y mixture substitution, all the other 23 viruses had H275Y substitution in the
NA protein. Sequence analysis revealed that the amino acid substitutions in the HA protein of influenza A (H1N1)
pdm09 viruses with H275Y substitution isolated from mainland China were similar to the viruses from clustered
cases reported in the United States, and the amino acid substitutions in the NA protein were similar to the viruses
reported in Sapporo, Japan in 2013–2014. All of the oseltamivir-resistant viruses in mainland China and Japan possessed
additional substitutions N386K, V241I and N369K in the NA protein, while most (>89 %) resistant-viruses from the United
States during the same period possess V241I and N369K and did not have the N386K substitution. The N386K
substitution was also exist in most sensitive viruses during the same period in mainland China. The amino acid
substitutions in both HA and NA protein differed from the clustered cases from Australia reported in 2011 with
additional substitutions. The drug-resistant influenza A(H1N1) pdm09 viruses were from patients without any
known NAIs medication history prior to sampling.
Conclusions: During the influenza season from September 2013 through March 2014 in Mainland China,
oseltamivir-resistant influenza A(H1N1)pdm09 viruses were much more frequently detected than ever since the
appearance of the virus in 2009.
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The pandemic of 2009 highlighted the importance of
global influenza viral surveillance for the detection of
new virus variants and the need of antiviral medications
to mitigate the public health impact of influenza. Oselta-
mivir is a drug commonly used for the prevention and
treatment of influenza. During the 2009 influenza pan-
demic, oseltamivir was used worldwide and has been
listed as a stockpiled drug in many countries in response
to influenza pandemics [1, 2].
After pandemic of 2009, influenza A (H1N1) pdm09
(abbreviated as H1N1pdm09 here after) viruses became
one of the seasonal influenza viruses. Prior to 2013, less
than 1 % of H1N1pdm09 viruses worldwide were
oseltamivir-resistant and most came from patients who
had received oseltamivir treatment before specimen col-
lection [3]. Most oseltamivir-resistant H1N1pdm09 vi-
ruses possessed histidine (H) to tyrosine (Y) change at
amino acid position 275 of the NA genes [4]. From
November 2013 through February 2014, a cluster of
H1N1pdm09 viruses with H275Y substitution were de-
tected in Sapporo, Japan. No epidemiological link were
identified among the patients except for one family in-
fection, and almost all of the patients had no exposure
to NAIs before specimen collection [5], leading to
concerns about local epidemics of oseltamivir-resistant
viruses. In mainland China, the routine antiviral suscep-
tibility surveillance to influenza virus with phenotypic
method was established in 2010. During the influenza
season from September 2013 through March 2014 in
Mainland China, oseltamivir-resistant H1N1pdm09 vi-
ruses were much more frequently detected than ever
since the appearance of the virus in 2009, and here we
report the findings to provide data for global surveil-
lance of antiviral-resistant influenza virus and guidance
in the choice of antiviral drugs for clinical treatment.
Results
Neuraminidase inhibition (NI) assay result
During the 2013–2014 influenza season, H1N1pdm09
virus, A (H3N2) virus and B virus were co-circulation in
Mainland China. In the NI assay, 1123 H1N1pdm09,
558 A (H3N2), and 918 influenza B viruses were tested
for susceptibility to oseltamivir and zanamivir. Twenty-
four H1N1pdm09 viruses exhibited more than 200-fold
elevated 50 % inhibitory concentration (IC50, the con-
centration of drug required to inhibit a standardized
amount of NA activity by 50 %) for oseltamivir com-
pared to the mean IC50 of oseltamivir sensitive reference
virus A/California/07/2009 (275H), which was used as a
run control and can provide enough data points to
calculate a mean IC50. The median IC50 of oseltamivir for
these 24 viruses was 251.68 nM and ranged from 64.85
nM to 478.65 nM, while the median IC50 of zanamivir forthese viruses was 0.21 nM, ranging from 0.16 nM to
0.41 nM (Table 1). Accord to the WHO AVWG (antiviral
susceptibly expert working group) criteria [6], the above
results were interpreted as highly reduced inhibition by
oseltamivir but normal inhibition by zanamivir.
Epidemiological characteristics of oseltamivir-resistant
viruses
These 24 viruses with highly reduced susceptibility to
oseltamivir were distributed throughout the influenza
season with varied proportions (Table 2), and most of
the oseltamivir-resistant viruses were isolated from clin-
ical specimens collected in December 2013 (Table 2).
The 24 viruses were actually collected from 23 pa-
tients, as two viruses, A/Shanghai-Changning/SWL1621/
2013 egg isolate and A/Shanghai-Changning /SWL1621/
2013 Madin-Darby canine kidney (MDCK) cell isolate
were isolated from the same sample. All samples were col-
lected from the hospital outpatients, including 11 females
and 12 males. The median age was 19 years, including 5
children between 1 and 6 years old; the maximum age was
71 years, and the minimum age was 1 year. All 23 patients
with NA H275Y virus had no history of exposure to NAIs
before sample collection except 6 with unknown history
(Table 1). Three cases were from the same district of
Chongqing province, the rest were from different regions
of 14 provinces and municipalities in northern and south-
ern China, and all were sporadic cases without known epi-
demiological relationship. The collecting dates of the 3
viruses from the same district were approximately 10 days
apart from each other and the 3 patients had no common
epidemiological exposure history.
Phylogeny analysis of NA and HA genes from oseltamivir-
resistant viruses
Representative H1N1pdm09 viruses isolated in mainland
China during the 2013–2014 influenza season were
analyzed phylogenetically, and in together with H275Y
mutant H1N1pdm09 viruses detected in Sapporo, Japan
[5] and United States [7] in 2013–2014 and in the
Australia cluster in 2011 [8]. Phylogenetic analysis of
NA (Fig. 1a) and HA (Fig. 1b) gene sequences showed,
in both phylogenetic trees, that the oseltamivir-resistant
viruses did not emerge from a common source. However,
the oseltamivir-resistant viruses from Mainland China
were genetically similar to those from the Sapporo cluster.
The H1N1pdm09 viruses from mainland China collected
during the 2013–2014 influenza season belonged to the
same clade, and oseltamivir-resistant viruses were gener-
ally scattered among the sensitive viruses.
Genetic characteristics of oseltamivir-resistant viruses
Twenty three of the 24 viruses possessed H275Y substi-
tution, while A/Chongqing-Yuzhong/SWL11434/2013
Table 2 The time distribution of H1N1pdm09 virus with highly
reduced sensitivity to oseltamivir during the 2013–2014 influenza





No. of viruses with highly reduced
sensitivity to Oseltamivir (%)
Sep-2013 35 2 (5.71 %)
Oct-2013 32 1 (3.13 %)
Nov-2013 113 4 (3.54 %)
Dec-2013 226 11 (4.87 %)
Jan-2014 150 4 (2.67 %)
Feb-2014 345 1 (0.29 %)
Mar-2014 222 1 (0.45 %)
Total 1123 24 (2.14 %)







IC50 (nM) Neuraminidase inhibitor
exposure historyOseltamivir Zanamivir
A/Beijing-Xichengnanpian/SWL11619/2013 2013-09-29 C2 + C1 27/F 242.80 0.18 No
A/Sichuan-Wuhou/SWL2259/2013 2013-09-30 E1 + E1 29/F 348.55 0.17 No
A/Chongqing-Yuzhong/SWL11434/2013 2013-10-12 E1 + E1 3/F 64.85 0.25 Unknown
A/Sichuan-Qingyang/SWL1599/2013 2013-11-03 C1 + C1 7/M 283.80 0.21 No
A/Hubei-Wuchang/SWL1322/2013 2013-11-09 C2 + C1 30/F 257.90 0.22 Unknown
A/Chongqing-Banan/SWL1690/2013 2013-11-11 C2 + C1 15/F 176.60 0.23 No
A/Chongqing-Banan/SWL1732/2013 2013-11-21 E2 + E1 7/F 237.50 0.30 No
A/Hunan-Furong/SWL1543/2013 2013-12-02 C2 + C1 51/F 277.85 0.20 No
A/Fujian-Gulou/SWL11609/2013 2013-12-03 E1 + E1 27/F 401.15 0.27 Unknown
A/Shanghai-Changning/SWL1621/2013 2013-12-03 E3 + E1 63/F 269.60 0.32 No
A/Shanghai-Changning/SWL1621/2013 C1 + C1 210.65 0.27
A/Chongqing-Banan/SWL1804/2013 2013-12-03 C1 + C1 71/M 287.80 0.21 No
A/Chongqing-Fuling/SWL1638/2013 2013-12-05 C2 + C1 15/M 245.45 0.17 No
A/Hubei-Xiangcheng/SWL1750/2013 2013-12-05 C1 + C1 1/F 187.90 0.17 No
A/Guangxi-Gangbei/SWL1481/2013 2013-12-17 C1 + C1 14/M 272.25 0.20 No
A/Heilongjiang-Daoli/SWL1480/2013 2013-12-17 C3 + C1 9/M 148.11 0.21 Unknown
A/Heilongjiang-Saertu/SWL1655/2013 2013-12-18 C2 + C1 17/M 121.47 0.20 Unknown
A/Guangdong-Liwan/SWL1865/2013 2013-12-18 C2 + C1 24/M 244.30 0.19 No
A/Hubei-Fancheng/SWL210/2014 2014-01-05 C1 + C1 19/M 301.55 0.21 No
A/Jilin-Longshan/SWL117/2014 2014-01-07 C1 + C1 39/M 216.75 0.18 No
A/Guizhou-Nanming/SWL1108/2014 2014-01-08 C1 + C1 3/M 190.40 0.16 Unknown
A/Hunan-Tianyuan/SWL129/2014 2014-01-08 C1 + C1 3/F 298.60 0.24 No
A/Neimenggu-Yuquan/SWL1155/2014 2014-02-27 E2 + E1 38/M 262.75 0.41 No
A/Jiangxi-Yushui/SWL1220/2014 2014-03-12 C2 + C1 1/M 478.65 0.37 No
A/Califorina/07/2009(275H) 0.30 0.15
A/North Carolina/39/2009(H275Y) 201.27 0.18
aCollection date: Collection date of clinical specimen
bC: MDCK; E: embryonated egg. Number is passage number in cell/eggs
cF: Female; M: Male
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tions in the HA and NA protein may compensate the
destabilizing effect of H275Y substitution [9], we fur-
ther characterized the other amino acid substitutions
in the HA and NA protein of the oseltamivir-resistant
viruses (Tables 3 and 4).
These substitutions in the HA protein of the oseltamivir-
resistant viruses isolated from Mainland China were in
consistent with those of the United States viruses, but
more distinct from those of the Australian viruses, and
had one amino acid substitution (position 15) different
from those from the Sapporo cluster. In addition,
among all oseltamivir-resistant viruses from Mainland
China, A/Chongqing-Yuzhong/SWL 11434/2013 and
A/Fujian-Gulou/SWL11609/2013 had D222G amino
acid substitutions, and A/Chongqing-Banan/SWL 1732/
2013 had Q223R amino acid substitutions in the HA
Fig. 1 Phylogenetic analysis of the Neuraminidase (a) and hemagglutinin (b) genes of the H275Y mutant H1N1pdm09 Viruses isolated in mainland
China in 2013–2014 influenza season. The clustered H1N1pdm09 virus with H275Y mutation in NA gene reported in Japan in 2013–2014, the United
States in 2013–2014, and Australia in 2011 were indicated with a vertical line. The NA gene of the H275Y mutant H1N1pdm09 Viruses isolated
in mainland China in 2013–2014 influenza season were indicated Solid circle. A/ California /07/2009: reference virus with 275H; A/North Carolina/ 39/
2009: reference virus with H275Y. E: Embryonated egg isolate
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protein of H1N1pdm09 viruses were known to be associ-
ated with increased pathogenicity of the viruses [10–12].
However, all samples were collected from the outpatients
with mild disease and there was no severe case involved.
For the NA gene, the amino acid of oseltamivir-resistant
viruses isolated from mainland China were consistent with
those of the Japanese viruses, and more distinct with
that of Australian viruses. All of the oseltamivir-
resistant viruses from mainland China and the Sapporo
cluster possessed an additional N386K substitution,
besides two amino acid substitutions, V241I and N369K,
in the NA protein, which might compensate for the detri-
mental effect of the H275Y substitution on viral fitness [3].
The N386K substitution also occurred in most sensitive
viruses during in the same period in mainland China. No
specific HA gene mutation that may has a compensatory
role in replication of an oseltamivir-resistant influenza
virus was identified, comparing with the sensitive viruses
isolated from the same period in mainland China.Discussion
From September 2013 through March 2014, 24
H1N1pdm09 viruses with highly reduced sensitivity to
oseltamivir were detected in mainland China. The pro-
portion of resistant viruses was 2.14 % with highest
proportion of 5.71 % in September, which is higher
than the 1 % proportion worldwide in the previous year
[3], and similar to the proportion of 2 % for the circu-
lating viruses tested during the 2013–2014 influenza
season globally [13]. Except for H275Y substitution in
the NA protein, no other substitution previously re-
ported to be related to reduced susceptibility to oselta-
mivir was detected in the 24 resistant viruses.
One limitation of the study is the lack of sequences
obtained from corresponding clinical specimens, because
only seasonal influenza virus isolates were submitted to
Chinese National Influenza Center and clinical speci-
mens were not available in the routine surveillance.
In terms of HA gene mutation, the H1N1pdm09
viruses with H275Y substitution isolated from mainland
Table 3 Characteristic of amino acids of the HA gene of oseltamivir-resistant H1N1pdm09 viruses isolated in mainland China in
2013–2014 influenza season
The boxed amino acids: Different amino acid substitutions of the viruses in comparison with A/California/07/2009
a: E: Embryonated egg isolate
b: Consensus sequence of the viruses from related clustered cases
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United States in 2013–2014. However, with regard to
the NA gene phylogenetic tree, the H1N1pdm09 viruses
isolated from mainland China were more similar to
those from Japan, in 2013–2014. Thus, it is possible that
the NA genes of the H1N1pdm09 viruses isolated from
mainland China and Japan shared the same origin. The
24 viruses were isolated from 23 cases from 14 provinces
or municipalities in mainland China with the first case
detected in September 2013 in China. The first clustered
case in Sapporo, Japan, was detected in November 2013.
Therefore, it is plausible that this virus was introduced
to Japan from China, and further mutation in the HA
and internal genes of the Japanese oseltamivir resistant
H1N1pdm09 viruses might enable this virus to have
caused a limited human-to-human transmission in
Sapporo, Japan and distinct from the sporadic H275Y
mutant viruses in Japan during the same period [5].
The seasonal influenza A (H1N1) viruses, which con-
tain an H275Y substitution in the NA protein, were first
detected in the Norway and subsequently elsewhere in
Europe in the early 2008, and then spread globally
within nine months, indicating that other amino acid
substitutions may have compensate the destabilizing ef-
fect from H275Y substitutions, thus enabling the spread
of viruses with the H275Y substitutions in the popula-
tion [9, 14]. After the H1N1pdm09 pandemic started, awidespread community cluster of an oseltamivir-
resistant H1N1pdm09 virus occurred in 2011 in New-
castle, Australia [8]. This resistant virus possessed the
H275Y substitution and three additional substitutions,
V241, N369K and N386S, in the NA protein. The V241I
and N369K substitutions, were reported to confer robust
viral fitness on the H275Y mutant virus [15, 16]. The
vast majority of recently circulating H1N1pdm09 viruses
possessed two amino acid substitutions, V241I and
N369K, in the NA protein [3]. The N386S substitution,
however, decreased the enzymatic activity and surface
expression of NA in infected cell, suggesting a negative
effect on virus fitness [15]. Similarly, the 24 viruses from
mainland China and the viruses from Sapporo, Japan
possessed the V241I, N369K and N386K substitutions.
However, most (>89 %) resistant-viruses from the United
States during the same period did not have the N386K
substitution [7]. Before the 2013–2014 influenza season,
H275Y mutant virus with V241I, N369K and N386K
substitutions was not detected in Mainland China, or
Japan [17]. It was reported the N386K destabilizes the
NA structure in the presence of the V241I and N369K
substitutions, causing a negative effect on virus fitness
[5]. Therefore, the structure of the mutant NA molecule
was less stable than that of the sensitive virus, presum-
ably because of the N386K substitution. In addition to
permissive NA mutations, other properties which might
Table 4 Characteristic of amino acids of the NA gene of oseltamivir-resistant H1N1pdm09 viruses isolated in mainland China in
2013–2014 influenza season
The boxed amino acids: Different amino acid substitution of the viruses in comparison with A/California/07/2009
aE: Embryonated egg isolate
b: Consensus sequence of the viruses from related clustered cases
Huang et al. Virology Journal  (2015) 12:96 Page 6 of 8provide an advantage to oseltamivir-resistant viruses and
facilitate their spread, should also be monitored.
Oseltamivir was widely used for influenza prevention
and treatment in 2009, and has been listed as a stock-
piled drug in response to influenza pandemics in many
countries after the 2009 pandemic. Emergence of the
clustered cases in Australia in 2011, in the United States
and Japan in 2013–2014, as well as the rise in the pro-
portion of oseltamivir-resistant H1N1pdm09 virus in
Mainland China from September 2013 through March
2014, with most of the patients weren’t being treated with
NAIs before sampling, has indicated that the human-to-
human transmission capacity of the H1N1 pdm09 viruses
with H275Y substitution is gradually increasing. Fortu-
nately, in our study, the H1N1pdm09 viruses with H275Y
substitution in NA protein were still sensitive to zanami-
vir. Therefore, in addition to strengthening the enhanced
surveillance of antiviral susceptibility of influenza virus,
we should pay attention to clinical drug choices, develop-
ment of new drugs, and strive to improve capabilities for
influenza prevention and control.
Conclusions
During the 2013–2014 influenza season, prevalence of
the oseltamivir-resistant H1N1pdm09 viruses were muchmore frequently detected than ever since the appearance
of the virus in 2009 in Mainland China. Most patients
infected with an oseltamivir-resistant H1N1pdm09 virus
had no prior exposure to oseltamivir. Our results
emphasize the need for surveillance for neuraminidase




H1N1pdm09 viruses isolated from specimens collected
from September 1, 2013 through March 31, 2014 were
obtained from the Chinese National Influenza Surveil-
lance Network, which covers 32 provinces in mainland
China (including the autonomous regions/municipalities
directly under the Central Government), including 408
network laboratories and 554 sentinel hospitals. The vi-
ruses were submitted to Chinese National Influenza
Center and propagated in either MDCK cells or embryo-
nated chicken eggs prior for testing. In addition, refer-
ence H1N1pdm09 virus variant, A/North Carolina/39/
2009 which carrying known marker (275Y) of highly
reduced susceptibility in the NI assays and the drug-
susceptible wild type counterparts, A/California/07/2009
(275H) were used in this study. The National Health and
Huang et al. Virology Journal  (2015) 12:96 Page 7 of 8Family Planning Commission deemed the data collection
for this surveillance to be part of the continuing public
health investigation and exempt from institutional re-
view board assessment.
Neuraminidase inhibition (NI) assay
The Chinese National Influenza Center used a fluorescence-
based assay, NA-Fluor™ kit (Applied Biosystems, Foster
City, CA, USA) to determine virus sensitivity to NAIs as
reported [18, 19]. Oseltamivir carboxylate was provided
by Hoffman-La Roche (Basel, Switzerland), zanamivir
was provided by Glaxo Smith Kline (Uxbrige, UK), and
Fluorescent was measured using 2104 multilabel reader
(Envision™, Perkin Elmer, USA) with the excitation and
emission wavelengths of 355 and 450 nm.
IC50 analysis
IC50 values were determined with the GraphPad Prism 5
software (GraphPad Software, La Jolla, CA, USA). Inter-
pretation of IC50 was performed using the WHO AVWG
criteria: the testing virus was compared with the
drug-sensitive reference virus, for influenza A viruses,
a < 10-fold increase in IC50 represents normal inhib-
ition, and a 10–-100 fold increase represents reduced
inhibition, while a > 100-fold increase is highly re-
duced inhibition [6].
HA and NA gene sequencing
Virus with an IC50 of ≥10-fold, compared to that of the
drug-sensitive reference virus, were analyzed by HA and
NA gene sequencing. Bio Robot M48 automated nucleic
acid extraction instrument (Qiagen, Germany) and its
compatible MagAttract Viral RNA M48 kit (96) (Qiagen,
Germany) were used for viral RNA extraction. One Step
reverse transcription-polymerase chain reaction (RT-PCR)
kit (Qiagen, Germany) was used for nucleotide sequences
amplification and the PCR reaction conditions were as
follows: 60 °C for 1 min; 42 °C for 20 min; 50 °C for
20 min; 95 °C for 15 min; then 94 °C for 30 s, 55 °C for
30 s, and 72 °C for 1 min for a total of 35 cycles; followed
by final extension at 72 °C for 10 min. PCR primers for
amplification of HA and NA genes were obtained from
the JCVI Genomic Sequencing Center for Infectious
Diseases website (http://gsc.jcvi.org/projects/msc/influ-
enza/). PCR products were purified using the QIAquick
96 PCR Purification kit (24) (Qiagen, Germany), followed
by sequencing reactions using BigDye® Terminator v3.1
Cycle Sequencing Kit (Applied Biosystems, Foster, USA).
The sequencing primers were M13F: 5′-TGTAAAAC
GACGGCCAGT-3′ and M13R: 5′-CAGGAAACAGC
TATG ACC-3′. The sequencing reaction conditions were
96 °C for 1 min; 25 cycles of 96 °C for 10 s, 50 °C for 5 s,
and 60 °C for 4 min. After sequencing products were
purified using the Bigdye® XTerminator™ Purificationkit (Applied Biosystems, Foster, USA), sequences were
read by 3730XL DNA sequencer (Applied Biosystems,
Foster, USA).
Sequence analysis
Sequences were assembled using the Seqman of the
Lasergene package (DNAStar, Corporation, USA). Nucleo-
tide alignments and phylogenetic tree were constructed
with MEGA version 5.0 software (the Biodesign Institute,
USA) using the neighbor-joining (NJ) method, and 1000
bootstrap replications were performed to evaluate the reli-
abilities. The H1N1pdm09 viruses from community in
Australia, Japan, and the United States, with H275Y in NA
gene, were analyzed in together with the Chinese viruses,
with sequences from the Global Initiative on Sharing
Avian Influenza Data (GISAID) [5, 7, 8]. The accession
number are present in the Additional file 1: Table S1.
Amino acids are described with the N1 numbering.
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